These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17136991)

  • 1. The workplace impact of acute exacerbations of chronic bronchitis (AECB); A literature review.
    Halpern MT; Polzin J; Higashi MK; Bakst A
    COPD; 2004; 1(2):249-54. PubMed ID: 17136991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review.
    Halpern MT; Higashi MK; Bakst AW; Schmier JK
    J Manag Care Pharm; 2003; 9(4):353-9. PubMed ID: 14613454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis.
    Perfetto EM; Mullins CD; Subedi P; Li-McLeod J
    Clin Ther; 2001 Oct; 23(10):1747-72. PubMed ID: 11726009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
    McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
    Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.
    Grossman R; Mukherjee J; Vaughan D; Eastwood C; Cook R; LaForge J; Lampron N
    Chest; 1998 Jan; 113(1):131-41. PubMed ID: 9440580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin.
    Li-McLeod J; Perfetto EM
    Manag Care Interface; 2001 Feb; 14(2):52-9. PubMed ID: 11228817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing economic outcomes in acute exacerbations of chronic bronchitis.
    Destache CJ
    Pharmacotherapy; 2002 Jan; 22(1 Pt 2):12S-17S; discussion 30S-32S. PubMed ID: 11791624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.
    Torrance G; Walker V; Grossman R; Mukherjee J; Vaughan D; La Forge J; Lampron N
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):499-520. PubMed ID: 10662396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of treating lower respiratory tract infections.
    Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
    Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis.
    Destache CJ; Dewan N; O'Donohue WJ; Campbell JC; Angelillo VA
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():107-13. PubMed ID: 10225580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment cost of acute exacerbations of chronic bronchitis.
    Niederman MS; McCombs JS; Unger AN; Kumar A; Popovian R
    Clin Ther; 1999 Mar; 21(3):576-91. PubMed ID: 10321424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equal effectiveness of older traditional antibiotics and newer broad-spectrum antibiotics in treating patients with acute exacerbations of chronic bronchitis.
    Peng CC; Aspinall SL; Good CB; Atwood CW; Chang CC
    South Med J; 2003 Oct; 96(10):986-91. PubMed ID: 14570342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotics in the treatment of acute exacerbations of chronic bronchitis.
    Dever LL; Shashikumar K; Johanson WG
    Expert Opin Investig Drugs; 2002 Jul; 11(7):911-25. PubMed ID: 12084002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy.
    Saint S; Flaherty KR; Abrahamse P; Martinez FJ; Fendrick AM
    Clin Ther; 2001 Mar; 23(3):499-512. PubMed ID: 11318083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of gemifloxacin: results from the GLOBE study.
    Halpern MT; Palmer CS; Zodet M; Kirsch J
    Am J Health Syst Pharm; 2002 Jul; 59(14):1357-65. PubMed ID: 12132563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of chronic bronchitis and acute infective exacerbations of chronic bronchitis.
    Kim N; Leeper KV
    Semin Respir Crit Care Med; 2000; 21(2):73-8. PubMed ID: 16088720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis.
    Blasi F; Ewig S; Torres A; Huchon G
    Pulm Pharmacol Ther; 2006; 19(5):361-9. PubMed ID: 16289762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis.
    Wilson R; Jones P; Schaberg T; Arvis P; Duprat-Lomon I; Sagnier PP;
    Thorax; 2006 Apr; 61(4):337-42. PubMed ID: 16449273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management.
    Hayes D; Meyer KC
    Drugs Aging; 2007; 24(7):555-72. PubMed ID: 17658907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review.
    Schmier JK; Halpern MT; Higashi MK; Bakst A
    Qual Life Res; 2005 Mar; 14(2):329-47. PubMed ID: 15892423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.